{"created":"2023-06-20T15:47:20.468215+00:00","id":1879,"links":{},"metadata":{"_buckets":{"deposit":"a51b537a-cdd8-4ba0-9e22-12da656624f7"},"_deposit":{"created_by":4,"id":"1879","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"1879"},"status":"published"},"_oai":{"id":"oai:hama-med.repo.nii.ac.jp:00001879","sets":["1:11"]},"author_link":["4801","4802","4803","4804","4805","4806","4807","4808","4809","4810","4811","4812","4813","4814","4815","4816"],"item_3_biblio_info_5":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2009-11-22","bibliographicIssueDateType":"Issued"},"bibliographicPageStart":"408","bibliographicVolumeNumber":"9","bibliographic_titles":[{"bibliographic_title":"BMC Cancer","bibliographic_titleLang":"en"}]}]},"item_3_description_9":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Background: Protracted low-dose concurrent chemotherapy combined with radiation has been proposed for enhanced treatment results for esophageal cancer. We evaluated the efficacy and the toxicity of a novel regimen of daily low-dose nedaplatin (cis-diammine-glycolatoplatinum) and continuous infusion of 5-fluorouracil (5-FU) with radiation in patients with esophageal squamous cell carcinoma. Methods: Between January 2003 and June 2008, 33 patients with clinical stage I to IVB esophageal squamous cell carcinoma were enrolled. Nedaplatin (10 mg/body/day) was administered daily and 5-FU (500 mg/body/day) was administered continuously for 20 days. Fractionated radiotherapy for a total dose of 50.4-66 Gy was administered together with chemotherapy. Additional chemotherapy with nedaplatin and 5-FU was optionally performed for a maximum of 5 courses after chemoradiotherapy. The primary end-point of this study was to evaluate the tumor response, and the secondary end-points were to evaluate the toxicity and the overall survival. Results: Twenty-two patients (72.7%) completed the regimen of chemoradiotherapy. Twenty patients (60.6%) achieved a complete response, 10 patients (30.3%) a partial response. One patient (3.0%) had a stable disease, and 2 (6.1%) a progressive disease. The overall response rate was 90.9% (95% confidence interval: 75.7%-98.1%). For grade 3-4 toxicity, leukopenia was observed in 75.8% of the cases, thrombocytopenia in 24.2%, anemia in 9.1%, and esophagitis in 36.4%, while late grade 3-4 cardiac toxicity occurred in 6.1%. Additional chemotherapy was performed for 26 patients (78.8%) and the median number of courses was 3 (range, 1-5). The 1-, 2- and 3-year survival rates were 83.9%, 76.0% and 58.8%, respectively. The 1- and 2-year survival rates were 94.7% and 88.4% in patients with T1-3 M0 disease, and 66.2% and 55.2% in patients with T4/M1 disease. Conclusion: The treatment used in our study may yield a high complete response rate and better survival for each stage of esophageal squamous cell carcinoma. Trial registration: ClinicalTrials.gov Identifier: NCT00197444","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_3_publisher_6":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"BioMed Central Ltd","subitem_publisher_language":"en"}]},"item_3_relation_28":{"attribute_name":"出版社DOI","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1186/1471-2407-9-408","subitem_relation_type_select":"DOI"}}]},"item_3_rights_7":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright 2009 BioMed Central Ltd","subitem_rights_language":"en"}]},"item_3_source_id_19":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"14712407","subitem_source_identifier_type":"ISSN"}]},"item_3_version_type_32":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Osawa, Satoshi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"4801","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Furuta, Takahisa","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"4802","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sugimoto, Ken","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"4803","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kosugi, Takashi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"4804","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Terai, Tomohiro","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"4805","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yamade, Mihoko","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"4806","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Takayanagi, Yasuhiro","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"4807","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Nishino, Masafumi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"4808","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Hamaya, Yasushi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"4809","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kodaira, Chise","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"4810","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yamada, Takanori","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"4811","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Iwaizumi, Moriya","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"4812","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Takagaki, Kosuke","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"4813","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yoshida, Ken-ichi","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"4814","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Kanaoka, Shigeru","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"4815","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ikuma, Mutsuhiro","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"4816","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-08-27"}],"displaytype":"detail","filename":"BMCCancer-2009_11-408.pdf","filesize":[{"value":"806.9 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"BMCCancer-2009_11-408.pdf","url":"https://hama-med.repo.nii.ac.jp/record/1879/files/BMCCancer-2009_11-408.pdf"},"version_id":"f2488fdc-adcc-4ae0-a6bc-6d91334c53ee"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma.","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma.","subitem_title_language":"en"}]},"item_type_id":"3","owner":"4","path":["11"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2013-08-27"},"publish_date":"2013-08-27","publish_status":"0","recid":"1879","relation_version_is_last":true,"title":["Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma."],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2023-08-02T02:08:27.529891+00:00"}